Myotonic Dystrophy Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Posted on
by

The Myotonic Dystrophy clinical trial analysis report delivers important insights into ongoing research of 22+ pipeline Myotonic Dystrophy drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

(Albany, US) September 28, 2026 – DelveInsight’s “Myotonic Dystrophy Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Myotonic Dystrophy pipeline landscape. It covers the Myotonic Dystrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myotonic Dystrophy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in understanding the Myotonic Dystrophy Treatment Landscape @ https://www.delveinsight.com/report-store/myotonic-dystrophy-pipeline-insight

Key Takeaways from the Myotonic Dystrophy Pipeline Report

  • DelveInsight’s Myotonic Dystrophy pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Myotonic Dystrophy treatment.

  • The companies with Myotonic Dystrophy drug candidates in the most advanced stage, i.e., Phase III, include Novartis AG, and others.

  • The leading Myotonic Dystrophy companies include Novartis AG, Arrowhead Pharmaceuticals, Inc., Arthex Biotech, Sanofi, DYNE Therapeutics, PepGen Inc., Vertex Pharmaceuticals Incorporated, AMO Pharma, Harmony Biosciences, Ionis Pharmaceuticals, Sarepta Therapeutics, Inc., Juvena Therapeutics Inc., and others.

  • Promising Myotonic Dystrophy pipeline therapies include Del-desiran (AOC 1001), ARO-DM1, ATX-01, SAR446268, DYNE-101, PGN-EDODM1, VX-670, Tideglusib (AMO-02), Pitolisant, IONIS-877864, SRP-1003, JUV-161, and others.

Gain in-depth knowledge of key Myotonic Dystrophy clinical trials, emerging drugs, and market opportunities @ Myotonic Dystrophy Clinical Trials Assessment

Myotonic Dystrophy Overview

Myotonic dystrophy is a chronic, progressive, autosomal dominant disorder characterized by muscle weakness and myotonia, the delayed relaxation of muscles after contraction. There are two major forms: myotonic dystrophy type I (DM1), known as Steinert disease, and myotonic dystrophy type II (DM2), or proximal myotonic myopathy, a milder variety. These are progressive, multisystem genetic disorders. Clinical presentation ranges from asymptomatic electrical myotonia to severe weakness and disability, including cardiac conduction defects, infertility, cataracts, and insulin resistance.

The disorder is inherited and caused by mutations in specific genes. DM1 results from mutations in the DMPK gene, while DM2 is caused by mutations in the CNBP gene. In both types, the underlying defect is an abnormal repetition of a DNA segment, creating an unstable region within the gene. Larger expansions are associated with more pronounced disease severity. These abnormal repeats produce excess messenger RNA that is toxic to cells and disrupts the production of multiple proteins, contributing to the multisystem nature of the disorder.

Main symptoms include progressive muscle weakness, muscle wasting (atrophy), and myotonia. The condition can also affect the heart, eyes, and endocrine system, leading to cardiac conduction abnormalities, cataracts, and metabolic disturbances. Severity and progression vary by type and by individual.

There is currently no definitive cure, and treatment focuses on managing symptoms and complications. This may include medications to control myotonia, physical therapy to maintain muscle strength and function, and assistive devices when needed. Cardiac, respiratory, and metabolic complications are treated individually to improve quality of life, with the aim of slowing progression and reducing complications rather than addressing the underlying genetic cause.

Myotonic Dystrophy Emerging Drugs Profile

Del-desiran (AOC 1001): Novartis AG

Del-desiran, built on Avidity’s AOC platform technology, is designed to address the underlying genetic cause of DM1 by reducing levels of toxic DMPK mRNA. It consists of a proprietary monoclonal antibody that binds to transferrin receptor 1 (TfR1), conjugated to an siRNA that targets DMPK mRNA. Del-desiran has received Breakthrough Therapy, Orphan Drug, and Fast Track designations from the U.S. FDA and Orphan designation from the European Medicines Agency (EMA). It was also the first investigational treatment for DM1 to receive Orphan Drug designation in Japan. The drug was developed by Avidity Biosciences, which has been fully acquired by Novartis AG. It is currently in the Phase III stage of development for Myotonic Dystrophy.

ARO-DM1: Arrowhead Pharmaceuticals, Inc.

ARO-DM1 is an RNA interference (RNAi) conjugate designed to specifically silence DMPK mRNA in skeletal muscle. Silencing aberrantly transcribed DMPK mRNA may halt CUGexp-related spliceopathies in patients with DM1, leading to improved muscle strength and function. It belongs to the class of RNA therapeutics. Preclinical data show greater than 80% silencing of DMPK in skeletal muscle, maintained for longer than 85 days. The drug is currently in the Phase II stage of development for Myotonic Dystrophy.

ATX-01: Arthex Biotech

ATX-01 is an antimiR oligonucleotide designed to target microRNA 23b (miR-23b), which is involved in the pathogenesis of DM1. In human DM1 myoblast cell lines and two murine models, it has shown a unique dual mechanism of action that reduces toxic DMPK mRNA and increases MBNL protein production. It was discovered through ARTHEx’s in-house discovery engine, built to identify, design, and optimize novel gene expression modulators and ensure their preferential delivery to affected tissues. The drug is currently in the Phase I/II stage of development for Myotonic Dystrophy.

SAR446268: Sanofi

SAR446268 employs a vectorized RNA interference (RNAi) approach to silence DMPK expression through a single administration. By reducing DMPK transcripts, the gene therapy aims to eliminate the abnormal and toxic RNA foci responsible for splicing defects in muscle tissue, restoring normal splicing and improving muscular function. This approach has the potential to address key symptoms including progressive muscle weakness, myotonia, and effects on the heart, lungs, and endocrine system. The U.S. FDA granted fast track designation to SAR446268 in September 2025. The drug is currently in the Phase I/II stage of development for Myotonic Dystrophy.

The Myotonic Dystrophy Pipeline Report Provides Insights Into

  • Detailed insights about companies developing therapies for Myotonic Dystrophy, with aggregate therapies developed by each company.

  • Therapeutic candidates segmented into early-stage, mid-stage, and late-stage development for Myotonic Dystrophy treatment.

  • Targeted therapeutics development by Myotonic Dystrophy companies, with respective active and inactive (dormant or discontinued) projects.

  • Myotonic Dystrophy drugs under development by stage of development, route of administration, product type, and molecule type.

  • Detailed analysis of collaborations (company-company and company-academia), licensing agreements, mergers and acquisitions, and financing details for future advancement of the Myotonic Dystrophy market.

Uncover critical updates on therapeutic innovations and their potential impact on patients @ Myotonic Dystrophy Unmet Needs

Myotonic Dystrophy Companies

Novartis AG, Arrowhead Pharmaceuticals, Inc., Arthex Biotech, Sanofi, DYNE Therapeutics, PepGen Inc., Vertex Pharmaceuticals Incorporated, AMO Pharma, Harmony Biosciences, Ionis Pharmaceuticals, Sarepta Therapeutics, Inc., Juvena Therapeutics Inc., and others.

The Myotonic Dystrophy pipeline report provides the therapeutic assessment of pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:

  • Intra-articular

  • Intraocular

  • Intrathecal

  • Intravenous

  • Ophthalmic

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical

  • Transdermal

Myotonic Dystrophy products have been categorized under various Molecule types such as:

  • Oligonucleotide

  • Peptide

  • Small molecule

Transform your understanding of the Myotonic Dystrophy Pipeline! @ Myotonic Dystrophy Market Drivers and Barriers, and Future Perspectives

Scope of the Myotonic Dystrophy Pipeline Report

  • Coverage: Global

  • Myotonic Dystrophy Companies: Novartis AG, Arrowhead Pharmaceuticals, Inc., Arthex Biotech, Sanofi, DYNE Therapeutics, PepGen Inc., Vertex Pharmaceuticals Incorporated, AMO Pharma, Harmony Biosciences, Ionis Pharmaceuticals, Sarepta Therapeutics, Inc., Juvena Therapeutics Inc., and others.

  • Myotonic Dystrophy Pipeline Therapies: Del-desiran (AOC 1001), ARO-DM1, ATX-01, SAR446268, DYNE-101, PGN-EDODM1, VX-670, Tideglusib (AMO-02), Pitolisant, IONIS-877864, SRP-1003, JUV-161, and others.

  • Myotonic Dystrophy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

  • Myotonic Dystrophy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Access the Full Myotonic Dystrophy Pipeline Analysis Today! @ Myotonic Dystrophy Drugs and Companies

Table of Contents

  • Introduction

  • Executive Summary

  • Myotonic Dystrophy: Overview

  • Pipeline Therapeutics

  • Comparative Analysis

  • Therapeutic Assessment

  • Myotonic Dystrophy – DelveInsight’s Analytical Perspective

  • Late Stage Products (Phase III)

  • Mid-Stage Products (Phase II)

  • Early Stage Products (Phase I)

  • Preclinical and Discovery Stage Products

  • Inactive Products

  • Myotonic Dystrophy Key Companies

  • Myotonic Dystrophy Key Products

  • Myotonic Dystrophy – Unmet Needs

  • Myotonic Dystrophy – Market Drivers and Barriers

  • Myotonic Dystrophy – Future Perspectives and Conclusion

  • Myotonic Dystrophy Analyst Views

  • Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/myotonic-dystrophy-pipeline-insight